Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adenovirus Vector Standards Should Be Loosened For Healthier Patients

Executive Summary

FDA should loosen the standard for levels of replication-competent adenovirus in gene therapy products for all but the most severely immunocompromised patients, the Biological Response Modifiers Advisory Committee suggested July 13.

You may also be interested in...



Gene Therapy With Lentivirus Is Acceptable For Clinical Trials, ICH Panel Says

Lentiviral vectors are acceptable for use in human clinical trials but the safety studies required will depend on the patient population and disease indication under study, an International Conference on Harmonization workgroup said Sept. 9 during a gene therapy workshop in Vienna, Va

Gene Therapy With Lentivirus Is Acceptable For Clinical Trials, ICH Panel Says

Lentiviral vectors are acceptable for use in human clinical trials but the safety studies required will depend on the patient population and disease indication under study, an International Conference on Harmonization workgroup said Sept. 9 during a gene therapy workshop in Vienna, Va

Gene Therapy Product QA Documentation May Become Key IND Element - FDA

Manufacturing quality assurance documentation could become a key component of gene therapy IND submissions, FDA Cellular & Gene Therapies Division Director Philip Noguchi, MD, suggested April 5.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel